Argenx announces 2021 corporate priorities and highlights recent achievements across immunology pipeline

Breda, the netherlands – jan. 8, 2021 – argenx (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its fcrn antagonist, efgartigimod. additionally, the company announced interim data from the phase 2 culminate trial of cusatuzumab in development with cilag gmbh international, an affiliate of janssen, and provided financial guidance for 2021.
ARGX Ratings Summary
ARGX Quant Ranking